Global insights driving the market strategies of tomorrow.

Sales of weight loss drugs fall short of expectations Lilly (LLY.US) cuts full-year guidance

Market IntelWednesday, Oct 30, 2024 8:10 am ET

1min read

Zai Tong Finance APP noted that Eli Lilly (LLY.US) cut its full-year earnings forecast on Wednesday due to weaker-than-expected sales of its blockbuster weight loss drug, citing inventory issues. The company now expects full-year sales of $45.4 billion to $46 billion, down from the previous $46.6 billion. Eli Lilly has raised its full-year sales forecast twice this year.

Eli Lilly said that Zepbound sales in the quarter were $1.26 billion, below analysts' average estimate of $1.63 billion. All product sales were $11.4 billion, below analysts' average estimate of $12.2 billion.

Eli Lilly said that higher inventory levels of Zepbound and Mounjaro at wholesalers in the previous quarter had weighed on sales.

Eli Lilly reported Q3 revenue of $11.44 billion, up 20.5% YoY, missing market expectations; adjusted EPS of $1.18, below analysts' expectations of $1.51.

Obesity is one of the largest and fastest-growing areas of the pharmaceutical industry, with analysts estimating the weight loss treatment market will reach $130 billion by 2030. Eli Lilly's success in this area has made it one of the world's most valuable pharmaceutical companies.

Its competitors are Novo Nordisk, a Danish company that produces Ozempic and Wegovy. Both companies have struggled to produce enough weight loss drugs to meet what appears to be a growing demand, and both have invested billions of dollars to increase production capacity.

Disclaimer: the above is a summary showing certain market information. AInvest is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from a third party source. Communications displaying market prices, data and other information available in this post are meant for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit, or protect against loss in a down market.